<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643224</url>
  </required_header>
  <id_info>
    <org_study_id>TP01071</org_study_id>
    <nct_id>NCT03643224</nct_id>
  </id_info>
  <brief_title>DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation</brief_title>
  <acronym>Diamond-AFII</acronym>
  <official_title>A Prospective Clinical Evaluation of the DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the&#xD;
      DiamondTemp Ablation System for the treatment of drug refractory, symptomatic persistent&#xD;
      atrial fibrillation in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DIAMOND-AF II Study is a prospective, non-randomized (single-group assignment) trial&#xD;
      being performed at multiple centers in the United States, Canada and Europe to evaluate the&#xD;
      safety and effectiveness of the DiamondTemp Ablation System for the treatment of patients&#xD;
      with persistent atrial fibrillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of device or procedure related Serious Adverse Events measured at 7 days in all subjects</measure>
    <time_frame>7 days after the index ablation procedure</time_frame>
    <description>Freedom from a composite of pre-specified Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of device or procedure related clinically significant tamponade/perforation measured at 30 days in all subjects.</measure>
    <time_frame>30 days after the index ablation procedure</time_frame>
    <description>Freedom from clinically significant tamponade/perforation occurring through 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of symptomatic pulmonary vein stenosis and atrioesophageal fistula through 6-months in all subjects.</measure>
    <time_frame>6 months after the index ablation procedure</time_frame>
    <description>Freedom from symptomatic pulmonary vein stenosis and atrioesophageal fistula through 6-months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of documented symptomatic atrial fibrillation, atrial flutter and atrial tachycardia episodes for all subjects.</measure>
    <time_frame>Between the blanking period (3-month follow-up post-ablation procedure) through the end of the effectiveness evaluation period (12-month follow-up post-ablation procedure).</time_frame>
    <description>Freedom from documented symptomatic atrial fibrillation (AF), atrial flutter* (AFL) and atrial tachycardia (AT) episodes following the blanking period through the end of the effectiveness evaluation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of device or procedure related Serious Adverse Events measured at 30 days in all subjects.</measure>
    <time_frame>30 days after the index ablation procedure</time_frame>
    <description>Freedom from a composite of pre-specified Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of documented symptomatic atrial fibrillation, atrial flutter and atrial tachycardia episodes in the absence of class I and II anti-arrhythmic drug therapy for all subjects.</measure>
    <time_frame>Between the blanking period (3-month follow-up post-ablation procedure) through the end of the effectiveness evaluation period (12-month follow-up post-ablation procedure).</time_frame>
    <description>Freedom from documented symptomatic and asymptomatic AF, AT and AFL episodes following the blanking period through 12-month follow-up post-ablation procedure in the absence of class I and III anti-arrhythmic drug therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of asymptomatic pericardial effusion of 1cm or more in size</measure>
    <time_frame>30 days after the index ablation procedure</time_frame>
    <description>Rate of asymptomatic pericardial effusion of 1cm or more in size as documented by echocardiography up to 30 days following the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of asymptomatic AF, AFL* or AT episodes through the effectiveness evaluation period lasting ≥30 seconds in duration by ECG or ECG monitoring system</measure>
    <time_frame>Between the blanking period (3-month follow-up post-ablation procedure) through the end of the effectiveness evaluation period (12-month follow-up post-ablation procedure).</time_frame>
    <description>Freedom from documented asymptomatic AF, AFL* or AT episodes through the effectiveness evaluation period lasting ≥30 seconds in duration by ECG or ECG monitoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute procedural success</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Rate of acute procedural success, defined as confirmation of electrical isolation of PVs via assessment of entrance block at least 20 minutes following the last ablation around the respective PV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of single procedure success</measure>
    <time_frame>12 months after the index ablation procedure</time_frame>
    <description>Rate of single procedure success defined as the rate of subjects treated with one single ablation procedure for the entire enrollment period and with freedom from documented symptomatic AF, AT and AFL* at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occurrence of electrically reconnected PVs following a 20-minute waiting period</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Rate of occurrence of electrically reconnected PVs following a 20-minute waiting period assessed by entrance block at index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulated changes in Quality of Life (QOL) using the Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire</measure>
    <time_frame>Between 6 months and 12 months after the index ablation procedure</time_frame>
    <description>Accumulated changes in QOL using the AFEQT Questionnaire from baseline through 6 and 12 months following ablation procedure.&#xD;
Section 1 measures occurrence of atrial fibrillation by asking the subject if they are in atrial fibrillation. If they answer &quot;No&quot;, it asks for the last time they had atrial fibrillation ranging from the subject were never aware of having atrial fibrillation (minimum) to more than 1 year ago (maximum).&#xD;
Section 2 measures how atrial fibrillation affects the subject's quality of life by asking a series of 20 questions that the subject rates on a scale of 1 to 7, how much was the subject bothered by their atrial fibrillation, one being &quot;Not at all bothered&quot; and 7 being &quot;Extremely bothered&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological changes measured using the National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Between baseline and 12 months after the index ablation procedure</time_frame>
    <description>The NIHSS which is comprised of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score possible is 0.&#xD;
1a. Level of Consciousness (LOC) 0 - 3&#xD;
1b. LOC Questions 0 - 2&#xD;
1c. LOC Commands 0 - 2 2. Best Gaze 0 - 2 3. Visual 0 - 3 4. Facial Palsy 0 - 3 5. Motor Arm. 0 - 4 or UN = Amputation or joint fusion. Scored for both left and right arms.&#xD;
6. Motor Leg. 0 - 4 or UN = Amputation or joint fusion. Scored for both left and right legs.&#xD;
7. Limb Ataxia. 0 - 2 or UN = Amputation or joint fusion 8. Sensory. 0 - 2 9. Best Language. 0 - 3 10. Dysarthria. 0 - 2 or UN = Intubated or other physical barrier. 11. Extinction and Inattention. 0 - 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total procedure time (minutes)</measure>
    <time_frame>Immediately after the index ablation procedure</time_frame>
    <description>Total procedure time (minutes), defined as time of investigational catheter insertion into the vasculature to time of last procedural ablation catheter removed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time to achieve initial PVI (minutes)</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Time to achieve initial PVI at index procedure (minutes), defined as time of delivery of first RF ablation with the investigational catheter until confirmation of PVI via entrance block following a 20-minute waiting period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to perform first-pass PV antral isolation</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Ability to perform first-pass PV antral isolation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total treatment device time (minutes)</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Total treatment device time (minutes), defined as time of delivery of first RF ablation with investigational catheter to removal of the investigational catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean cumulative RF Time (minutes).</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Mean cumulative RF Time (minutes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of RF ablations (seconds)</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Mean duration of RF ablations (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fluid infused through the investigational catheter (mL)</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Total fluid infused through the investigational catheter (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fluoroscopy time (minutes)</measure>
    <time_frame>Day of index ablation procedure</time_frame>
    <description>Total fluoroscopy time (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of re-hospitalizations due to atrial fibrillation recurrence.</measure>
    <time_frame>Between the blanking period (3-month follow-up post-ablation procedure) through the end of the effectiveness evaluation period (12-month follow-up post-ablation procedure).</time_frame>
    <description>Number of re-hospitalizations due to atrial fibrillation recurrence after blanking period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of asymptomatic AF, AFL* or AT episodes through the effectiveness evaluation</measure>
    <time_frame>Between the blanking period (3-month follow-up post-ablation procedure) through the end of the effectiveness evaluation period (12-month follow-up post-ablation procedure).</time_frame>
    <description>Freedom from documented asymptomatic AF, AFL* or AT episodes during effectiveness evaluation period in the absence of class I and III anti-arrhythmic drug therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <description>A procedure will be performed using a radiofrequency ablation catheter.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Above eighteen (18) years of age or of legal age to give informed consent specific to&#xD;
             state and national law.&#xD;
&#xD;
          2. Subjects with a history of documented symptomatic, persistent atrial fibrillation with&#xD;
             1) a physician's note documenting a continuous AF episode lasting longer than 7 days&#xD;
             but less than 12 months and 2) a 24-hour Holter within 90 days of the ablation&#xD;
             procedure showing continuous AF.&#xD;
&#xD;
          3. Refractory, intolerant or contraindicated to at least one Class I or III&#xD;
             anti-arrhythmic (AAD) drug.&#xD;
&#xD;
          4. Suitable candidate for intra-cardiac mapping and ablation of arrhythmia.&#xD;
&#xD;
          5. Subject agrees to comply with study procedures and be available (geographically&#xD;
             stable) for follow-up visits for at least 12 months after enrollment.&#xD;
&#xD;
          6. Subject is willing and able to provide written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At time of enrollment and/or prior to procedure:&#xD;
&#xD;
          1. Continuous AF &gt;12 months (long-standing persistent AF)&#xD;
&#xD;
          2. Paroxysmal AF with longest episode &lt;7 days&#xD;
&#xD;
          3. AF secondary to electrolyte imbalance, thyroid disease or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          4. Rheumatic heart disease&#xD;
&#xD;
          5. Severe mitral regurgitation&#xD;
&#xD;
          6. Hypertrophic cardiomyopathy&#xD;
&#xD;
          7. LA diameter &gt;5.5 cm&#xD;
&#xD;
          8. Left ventricular ejection fraction (LVEF) &lt;40%&#xD;
&#xD;
          9. Currently NYHA Class III or IV or exhibits uncontrolled heart failure&#xD;
&#xD;
         10. Body Mass Index (BMI) &gt;42 kg/m2.&#xD;
&#xD;
         11. LA ablation, septal closure device or mitral valve surgical procedure at any time&#xD;
             prior to enrollment&#xD;
&#xD;
         12. Presence of intramural thrombus, tumor or abnormality that precludes vascular access,&#xD;
             catheter introduction or manipulation&#xD;
&#xD;
         13. Coagulopathy, bleeding diathesis or suspected procoagulant state&#xD;
&#xD;
         14. Sepsis, active systemic infection or fever (&gt;100.5 oF / 38 oC) within a week prior to&#xD;
             the ablation procedure&#xD;
&#xD;
         15. Significant restrictive or obstructive pulmonary disease or chronic respiratory&#xD;
             condition&#xD;
&#xD;
         16. Renal failure requiring dialysis or renal compromise that in the investigator's&#xD;
             judgement would increase risk to the subject or deem the subject inappropriate to&#xD;
             participate in the study.&#xD;
&#xD;
         17. Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used&#xD;
             in conjunction with the study or contrast sensitivity that cannot be adequately&#xD;
             pre-treated prior to the ablation procedure.&#xD;
&#xD;
         18. Positive pregnancy test results for female subjects of childbearing potential or&#xD;
             breast feeding.&#xD;
&#xD;
         19. Enrollment in a concurrent clinical study that in the judgement of the investigator&#xD;
             would impact study outcomes.&#xD;
&#xD;
         20. Acute or chronic medical condition that in the judgment of the investigator would&#xD;
             increase risk to the subject or deem the subject inappropriate to participate in the&#xD;
             study.&#xD;
&#xD;
         21. Life expectancy &lt;12 months based on medical history or the medical judgement of the&#xD;
             investigator.&#xD;
&#xD;
             Within 1 month of enrollment or just prior to procedure:&#xD;
&#xD;
         22. Documented LA thrombus upon imaging&#xD;
&#xD;
         23. Creatinine &gt;2.5mg/dl or creatinine clearance &lt;30mL/min&#xD;
&#xD;
             Within 3 months of enrollment:&#xD;
&#xD;
         24. Significant gastrointestinal (GI) bleed&#xD;
&#xD;
         25. Myocardial infarction (MI), unstable angina, cardiac surgery or coronary intervention&#xD;
&#xD;
             Within 6 months of enrollment:&#xD;
&#xD;
         26. Coronary artery bypass graft (CABG) procedure&#xD;
&#xD;
         27. Implant procedure performed for ICD, CRT leads or pacemaker&#xD;
&#xD;
         28. Documented stroke, CVA, TIA or suspected neurological event&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director, Heart Rhythm Program, Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Electrophysiology, Texas Cardiac Arrhythmia Institute at St. David's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonandy Barrientos, MS</last_name>
    <phone>2019529967</phone>
    <email>yonandy.barrientos@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sparks, RN</last_name>
    </contact>
    <investigator>
      <last_name>Anil Rajendra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck School Of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Perez, RN</last_name>
      <phone>323-442-7983</phone>
      <email>Silvia.Perez@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Doshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Schwartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health, Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Warrington, RN</last_name>
      <phone>407-303-9982</phone>
      <email>maggie.warrington@adventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Usman Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naushad Shaik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giancarlo Speziani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Heart Rhythm Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Bush, RN</last_name>
      <email>Jennifer.Bush2@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Dhanunjaya Lakkireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Cheatham, RN</last_name>
      <phone>601-982-7850</phone>
    </contact>
    <investigator>
      <last_name>Judson Colley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber S Jernigan, RN</last_name>
      <phone>662-377-7572</phone>
      <email>ANSchmitz@nmhs.net</email>
    </contact>
    <investigator>
      <last_name>James E Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalvert Polanco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luigi Di Biase, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Romero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trident Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <phone>512-458-9410</phone>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>Amin Al-Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodney Horton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Center</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y2P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>HITC8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Na Homolce</name>
      <address>
        <city>Praha</city>
        <state>Prague</state>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St Ann's University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut Klinicke a Experimentalni Mediciny (IKEM)</name>
      <address>
        <city>Praha</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Merkelová, RN</last_name>
      <email>ivana.merkelova@hdiczech.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Kautzner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petr Peichl, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frantisek Lehar, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 3</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique du Tonkin</name>
      <address>
        <city>Villeurbanne</city>
        <state>Lyon</state>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Pierre</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Institute GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Venezia</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ablation</keyword>
  <keyword>electrophysiology</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter</keyword>
  <keyword>persistent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

